The updated 2020 ASCO/CAP Guidelines for Estrogen and Progesterone Receptor Testing in Breast Cancer suggest retesting ER in cases of highly unusual ER‐negative or ER‐positive results.7, 8. This evidence concerns the gene ESR1 and breast cancer.